<DOC>
	<DOC>NCT02813265</DOC>
	<brief_summary>The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).</brief_summary>
	<brief_title>Safety and Efficacy of KPI-12 in Subjects With Dry Eye Disease</brief_title>
	<detailed_description>This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease.</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Have a documented clinical diagnosis of dry eye disease in both eyes Known hypersensitivity or contraindication to the investigational product(s) or components History of glaucoma, IOP&gt;21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye. Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within 30 days prior to screening. In the opinion of the Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ocular Discomfort</keyword>
	<keyword>Pain</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Hyperemia</keyword>
	<keyword>Dry Eye</keyword>
</DOC>